Diagnostic Performance of PI-RADS v2, Proposed Adjusted PI-RADS v2 and Biparametric Magnetic Resonance Imaging for Prostate Cancer Detection: A Preliminary Study

Diagnostic Performance of PI-RADS v2, Proposed Adjusted PI-RADS v2 and Biparametric Magnetic Resonance Imaging for Prostate Cancer Detection: A Preliminary Study

Purpose: To evaluate the diagnostic performance of PI-RADS v2, proposed adjustments to PI-RADS v2 (PA PI-RADS v2) and biparametric magnetic resonance imaging (MRI) for prostate cancer detection. Methods: A retrospective cohort of 224 patients with suspected prostate cancer was included from January...

Full description

Bibliographic Details
Main Authors:	Guan-Hui Cai, Qi-Hua Yang, Wen-Bo Chen, Qing-Yu Liu, Yu-Rong Zeng, Yu-Jing Zeng
Format:	Article
Language:	English
Published:	MDPI AG 2021-05-01
Series:	Current Oncology
Subjects:	prostate neoplasm prostate cancer multiparametric MRI PI-RADS Gleason score
Online Access:	https://www.mdpi.com/1718-7729/28/3/169

Similar Items

MRI Based Radiomics Compared With the PI-RADS V2.1 in the Prediction of Clinically Significant Prostate Cancer: Biparametric vs Multiparametric MRI
by: Tong Chen, et al.
Published: (2022-01-01)

The role of different PI-RADS versions in prostate multiparametric magnetic resonance tomography assessment
by: Paulius Aliukonis, et al.
Published: (2017-04-01)

Predictors of prostate cancer cetection in MRI PI-RADS 3 lesions – Reality of a terciary center
by: Débora Araújo, et al.
Published: (2023-12-01)

Comparison of Diagnostic Performance Between PI-RADS v2.1 and PI-RADS v2 for Prostate Cancer: A Meta-analysis
by: BAI Guojie, et al.
Published: (2023-10-01)

Interreader agreement in different PI-RADS systems in multiparametric prostate magnetic resonance imaging: A head-to-head comparison between PI-RADSv2 and v2.1
by: Merve Horoz, et al.
Published: (2021-01-01)

PI‐RADS 3 score: A retrospective experience of clinically significant prostate cancer detection
by: Andrés Camacho, et al.
Published: (2023-07-01)

Study of iron metabolism based on T2* mapping sequences in PI-RADS 3 prostate lesions
by: Wenhao D, et al.
Published: (2023-05-01)

Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer
by: Yu Zhang, et al.
Published: (2018-06-01)

Magnetic resonance semiotics of prostate cancer according to the PI-RADS classification. The clinical diagnostic algorithm of a study
by: A. S. Korobkin, et al.
Published: (2016-03-01)

Biparametric Prostate MRI Shows Similar Diagnostic Accuracy Rates for Prostate Cancer Detection with Multiparametric MRI
by: Faruk Yencilek, et al.
Published: (2022-09-01)

Improving the understanding of PI-RADS in practice: characters of PI-RADS 4 and 5 lesions with negative biopsy
by: Yu-Hao Wang, et al.
Published: (2023-01-01)

Prostate Imaging Reporting and Data System (PI-RADS) v 2.1: Overview and Critical Points
by: Chan Kyo Kim
Published: (2023-01-01)

Impact of Chronic Prostatitis on the PI-RADS Score 3: Proposal for the Addition of a Novel Binary Suffix
by: Sascha Merat, et al.
Published: (2021-03-01)

PI-RADS v2.1 evaluation of prostate “nodule in nodule” variants: clinical, imaging, and pathological features
by: MingHua Sun, et al.
Published: (2024-03-01)

Towards the Definition of Radiomic Features and Clinical Indices to Enhance the Diagnosis of Clinically Significant Cancers in PI-RADS 4 and 5 Lesions
by: Pietro Andrea Bonaffini, et al.
Published: (2023-10-01)

Machine Learning and Clinical-Radiological Characteristics for the Classification of Prostate Cancer in PI-RADS 3 Lesions
by: Michela Gravina, et al.
Published: (2022-06-01)

The Diagnostic Value of PI-RADS v2.1 in Patients with a History of Transurethral Resection of the Prostate (TURP)
by: Jiazhou Liu, et al.
Published: (2022-09-01)

PI-RADS v2.1: What has changed and how to report
by: Robin Scott, et al.
Published: (2021-06-01)

In prostatic transition zone lesions (PI-RADS v2.1): which subgroup should be biopsied?
by: Jihae An, et al.
Published: (2021-08-01)

The Impact of Prostate Volume on the Prostate Imaging and Reporting Data System (PI-RADS) in a Real-World Setting
by: Yannic Volz, et al.
Published: (2023-08-01)

Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer
by: Mou Li, et al.
Published: (2021-02-01)

Considering Predictive Factors in the Diagnosis of Clinically Significant Prostate Cancer in Patients with PI-RADS 3 Lesions
by: Caleb Natale, et al.
Published: (2021-12-01)

Intraobserver and Interobserver Agreement between Six Radiologists Describing mpMRI Features of Prostate Cancer Using a PI-RADS 2.1 Structured Reporting Scheme
by: Rafał Jóźwiak, et al.
Published: (2023-02-01)

PI-RADS v2.1 and PSAD for the prediction of clinically significant prostate cancer among patients with PSA levels of 4–10 ng/ml
by: Jing Wen, et al.
Published: (2024-03-01)

Transverse prostate maximum sectional area can predict clinically significant prostate cancer in PI-RADS 3 lesions at multiparametric magnetic resonance imaging
by: Caterina Gaudiano, et al.
Published: (2023-02-01)

The Application of Biopsy Density in Transperineal Templated-Guided Biopsy Patients With PI-RADS<3
by: Hai Zhu, et al.
Published: (2022-06-01)

Development and Validation of a Radiomics Nomogram for Predicting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions
by: Tianping Li, et al.
Published: (2022-01-01)

The Prognostic Value of PI-RADS Score in CyberKnife Ultra-Hypofractionated Radiotherapy for Localized Prostate Cancer
by: Marcin Miszczyk, et al.
Published: (2022-03-01)

Radiomics in PI-RADS 3 Multiparametric MRI for Prostate Cancer Identification: Literature Models Re-Implementation and Proposal of a Clinical–Radiological Model
by: Andrea Corsi, et al.
Published: (2022-10-01)

Assessment of DCE Utility for PCa Diagnosis Using PI-RADS v2.1: Effects on Diagnostic Accuracy and Reproducibility
by: Valentina Brancato, et al.
Published: (2020-03-01)

Multiparametric MRI and MR Spectroscopic Imaging of Prostate Lesions with Implementation of PI-RADS and Histopathological Correlation: A Prospective Analysis
by: Reddy Ravikanth, et al.
Published: (2019-01-01)

Prostate Cancer Detection with mpMRI According to PI-RADS v2 Compared with Systematic MRI/TRUS-Fusion Biopsy: A Prospective Study
by: Anja Sauck, et al.
Published: (2022-08-01)

Nomograms Combining PHI and PI-RADS in Detecting Prostate Cancer: A Multicenter Prospective Study
by: Yongheng Zhou, et al.
Published: (2023-01-01)

Clinical Utility of Prostate Health Index for Diagnosis of Prostate Cancer in Patients with PI-RADS 3 Lesions
by: Chung-Un Lee, et al.
Published: (2022-08-01)

Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with PI-RADS 3 Undergo Targeted Biopsy?
by: Enrique Gomez-Gomez, et al.
Published: (2021-07-01)

Machine learning-based radiomics model to predict benign and malignant PI-RADS v2.1 category 3 lesions: a retrospective multi-center study
by: Pengfei Jin, et al.
Published: (2023-03-01)

Development and validation of a nomogram for predicting prostate cancer based on combining contrast-enhanced transrectal ultrasound and biparametric MRI imaging
by: Wanxian Nong, et al.
Published: (2023-11-01)

Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies
by: Daniël F. Osses, et al.
Published: (2020-12-01)

Comparison of Targeted Biopsy and Combined Biopsy to Avoid Unnecessary Systematic Biopsy in Patients with PI-RADS 5 Lesions
by: Changwei Yuan, et al.
Published: (2023-11-01)

Prostate Imaging Reporting and Data System score (PI-RADS) and Glutathione S-transferase P1 methylation status (GST-P1) in the diagnosis of prostate cancer patients with borderline PSA values
by: Marius Stan, et al.
Published: (2022-10-01)